Malignant melanoma with BRAF V600E mutation

Malignant melanoma with BRAF V600E mutation is an aggressive neoplasm of the integumentary system arising from the malignant transformation of pigment-producing melanocytes The defining molecular feature is a specific somatic missense mutation in the *BRAF* proto-oncogene where valine is substituted by glutamic acid at codon 600, leading to constitutive, ligand-independent activation of the downstream MAPK/ERK kinase pathway This unconstrained signaling accelerates cellular proliferation, surviv...

The defining molecular feature is a specific somatic missense mutation in the *BRAF* proto-oncogene where valine is substituted by glutamic acid at codon 600, leading to constitutive, ligand-independent activation of the downstream MAPK/ERK kinase pathway This unconstrained signaling accelerates cellular proliferation, survival, and metastatic potential, most frequently manifesting in cutaneous lesions associated with intermittent ultraviolet radiation exposure

The defining molecular feature is a specific somatic missense mutation in the *BRAF* proto-oncogene where valine is substituted by glutamic acid at codon 600, leading to constitutive, ligand-independent activation of the downstream MAPK/ERK kinase pathway

This unconstrained signaling accelerates cellular proliferation, survival, and metastatic potential, most frequently manifesting in cutaneous lesions associated with intermittent ultraviolet radiation exposure

Identification of this actionable biomarker delineates a distinct therapeutic subset responsive to targeted kinase inhibition, notably within advanced, unresectable, or metastatic disease stages

Identification of this actionable biomarker delineates a distinct therapeutic subset responsive to targeted kinase inhibition, notably within advanced, unresectable, or metastatic disease stages